Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedAug 07, 2026
DataAggregated Company Financials
Companies1397
  • 7D0.8%
  • 3M13.7%
  • 1Y30.2%
  • YTD6.9%

Last week, the Healthcare industry hasn't moved much but Eli Lilly is up 3.2% in that time. The past year has been better, since the industry has gained 30% in that time. Earnings are forecast to grow by 20% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 07 Aug 2026US$7.0tUS$3.4tUS$113.7b26.2x61.2x2.1x
Sun, 05 Jul 2026US$7.0tUS$3.3tUS$122.0b25.8x57.4x2.1x
Tue, 02 Jun 2026US$6.4tUS$3.3tUS$122.4b23.2x52.2x1.9x
Thu, 30 Apr 2026US$6.1tUS$3.3tUS$122.0b22.9x50x1.9x
Sat, 28 Mar 2026US$6.1tUS$3.3tUS$126.0b21.7x48.5x1.9x
Mon, 23 Feb 2026US$6.6tUS$3.3tUS$128.1b26.6x51.1x2x
Wed, 21 Jan 2026US$6.5tUS$3.2tUS$136.3b27.8x48x2x
Fri, 19 Dec 2025US$6.4tUS$3.2tUS$135.2b26.6x47.6x2x
Sun, 16 Nov 2025US$6.2tUS$3.2tUS$133.4b25.9x46.8x2x
Tue, 14 Oct 2025US$5.9tUS$3.1tUS$137.9b24.1x42.9x1.9x
Thu, 11 Sep 2025US$5.8tUS$3.1tUS$137.7b22.7x41.9x1.9x
Sat, 09 Aug 2025US$5.3tUS$3.1tUS$138.6b22.9x38.5x1.7x
Mon, 07 Jul 2025US$5.6tUS$3.0tUS$127.9b24.3x43.4x1.8x
Wed, 04 Jun 2025US$5.4tUS$3.0tUS$127.2b23.6x42.5x1.8x
Fri, 02 May 2025US$5.5tUS$2.7tUS$117.5b25.2x46.7x2.1x
Sun, 30 Mar 2025US$5.6tUS$2.6tUS$81.6b26.4x69.1x2.1x
Tue, 25 Feb 2025US$5.8tUS$2.6tUS$80.7b26.5x72.1x2.2x
Thu, 23 Jan 2025US$6.0tUS$2.9tUS$78.9b28.2x75.6x2x
Sat, 21 Dec 2024US$5.7tUS$2.9tUS$78.2b27.1x72.7x1.9x
Mon, 18 Nov 2024US$5.9tUS$2.9tUS$76.6b27.6x77.4x2x
Wed, 16 Oct 2024US$6.2tUS$2.8tUS$59.2b30x104.9x2.2x
Fri, 13 Sep 2024US$6.3tUS$2.8tUS$60.3b30.2x103.8x2.2x
Sun, 11 Aug 2024US$6.0tUS$2.8tUS$55.3b30.4x108.9x2.1x
Tue, 09 Jul 2024US$6.1tUS$2.8tUS$62.2b30.2x98.5x2.2x
Thu, 06 Jun 2024US$6.2tUS$2.8tUS$64.1b30.6x96x2.2x
Sat, 04 May 2024US$6.0tUS$2.8tUS$65.2b31.1x92.3x2.1x
Mon, 01 Apr 2024US$6.4tUS$2.8tUS$84.0b33.4x75.7x2.3x
Wed, 28 Feb 2024US$6.3tUS$2.8tUS$85.8b31x73.5x2.3x
Fri, 26 Jan 2024US$6.3tUS$2.8tUS$90.9b32x69.3x2.2x
Sun, 24 Dec 2023US$6.2tUS$2.8tUS$91.5b32.6x67.4x2.2x
Tue, 21 Nov 2023US$5.8tUS$2.8tUS$90.7b27.8x63.6x2x
Thu, 19 Oct 2023US$5.8tUS$2.8tUS$99.8b26x58.5x2.1x
Sat, 16 Sep 2023US$6.0tUS$2.8tUS$98.6b28.9x61.3x2.2x
Mon, 14 Aug 2023US$6.2tUS$2.8tUS$99.1b28.5x62.5x2.2x
Price to Earnings Ratio

62.5x


Total Market Cap: US$6.2tTotal Earnings: US$99.1bTotal Revenue: US$2.8tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 61.2x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 4.7% per year over the last three years.
  • Revenues for these companies have grown 6.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market3.47%
Healthcare0.84%
Healthtech7.20%
Biotech1.93%
Medical Equipment1.63%
Pharma1.35%
Life Sciences0.78%
Healthcare Services-2.80%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 55.7x.
    • Analysts are expecting annual earnings growth of 18.6%, which is higher than its past year's earnings growth of 5.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 28% over the next 5 years.
  • However this is lower than its past earnings growth rate of 65% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 16% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.19k3.2%
+US$32.5b		86.0%PE39.8x
AMGN AmgenUS$404.854.4%
+US$9.7b		42.2%PE25x
PFE PfizerUS$26.205.2%
+US$7.4b		8.1%PE34.4x
ISRG Intuitive SurgicalUS$373.715.9%
+US$7.3b		-20.5%PE42.1x
INSM InsmedUS$132.5530.6%
+US$6.7b		21.3%PS35.1x

Latest News

LLY
US$1,191.94
Eli Lilly
7D
3.2%
1Y
86.0%
UNH
US$403.97
UnitedHealth Group
7D
-4.2%
1Y
65.1%
MRK
US$128.37
Merck
7D
-1.1%
1Y
59.7%
INSM
US$132.55
Insmed
7D
30.6%
1Y
21.3%
ABBV
US$243.87
AbbVie
7D
-5.3%
1Y
22.6%
AMGN
US$404.85
Amgen
7D
4.4%
1Y
42.2%
Narrative Update • Aug 06

AMGN: Fair Outlook Weighs Pipeline Execution Against Cybersecurity And Regulatory Risks

Amgen's updated analyst price target reflects a move higher, supported by recent upward revisions to earnings estimates and increased confidence from analysts in the company's Q2 performance and late stage pipeline catalysts, including MariTide and key cardiovascular programs. Analyst Commentary Recent Street research on Amgen shows a broadly constructive tone, with many firms lifting price targets after Q2 results while still flagging execution and timing risks around key programs such as MariTide and olpasiran.
DVA
US$180.67
DaVita
7D
-24.4%
1Y
41.5%
MDLN
US$34.51
Medline
7D
-11.8%
1Y
n/a
PFE
US$26.20
Pfizer
7D
5.2%
1Y
8.1%
Narrative Update • Aug 05

PFE: Pipeline Readouts And Legal Overhang Will Shape Post Covid Earnings Trajectory

The analyst fair value estimate for Pfizer has risen from $24.00 to $25.00 as analysts factor in updated pipeline expectations, modestly stronger profit margin assumptions, and recent Street price target moves that cluster in the mid to high $20s per share. Analyst Commentary Recent Street views on Pfizer sit in a fairly tight range in the mid to high US$20s, with most price targets clustered between US$25 and US$35.
CVS
US$96.22
CVS Health
7D
-8.6%
1Y
51.3%
Narrative Update • Aug 05

CVS: GLP 1 Expansion And Legal Risks Will Shape Future Earnings

The analyst price target for CVS Health has shifted from $111.92 to $114.88. This change reflects updated views from recent Street research that focuses on valuation, medical loss ratio trends, regulatory clarity, and ongoing growth investments across its healthcare services businesses.
CI
US$275.25
Cigna Group
7D
-4.3%
1Y
1.6%
ISRG
US$373.71
Intuitive Surgical
7D
5.9%
1Y
-20.5%
Narrative Update • Aug 04

ISRG: Slowing U.S. Procedures And ACA Risks Will Pressure Rich Expectations

The updated analyst price target for Intuitive Surgical moves from about $412 to $324. This reflects lower implied revenue growth and P/E assumptions, even as analysts highlight healthy procedure trends, strong profitability, and ongoing questions around U.S. procedure momentum, automation driven adoption, and Affordable Care Act related procedure risks.
REGN
US$772.11
Regeneron Pharmaceuticals
7D
4.6%
1Y
37.9%
SYK
US$337.43
Stryker
7D
-3.0%
1Y
-10.3%
ELV
US$391.40
Elevance Health
7D
4.0%
1Y
38.1%
ABT
US$107.96
Abbott Laboratories
7D
2.2%
1Y
-18.2%